Swiss National Bank Cuts Stake in Biogen Inc. $BIIB

Swiss National Bank cut its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 4.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 422,400 shares of the biotechnology company’s stock after selling 20,700 shares during the quarter. Swiss National Bank owned 0.29% of Biogen worth $59,170,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Elevation Point Wealth Partners LLC acquired a new position in Biogen during the 2nd quarter worth $25,000. Rothschild Investment LLC boosted its stake in shares of Biogen by 64.7% in the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 88 shares during the period. Accredited Wealth Management LLC grew its position in shares of Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after buying an additional 185 shares in the last quarter. WFA of San Diego LLC purchased a new stake in shares of Biogen during the second quarter worth approximately $32,000. Finally, True Wealth Design LLC lifted its stake in Biogen by 62.9% in the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 90 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BIIB. Mizuho raised their price objective on shares of Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. BMO Capital Markets upped their price objective on Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a research report on Friday, February 6th. Wells Fargo & Company raised their target price on Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Sunday, February 8th. Piper Sandler boosted their target price on Biogen from $157.00 to $177.00 and gave the stock a “neutral” rating in a research note on Monday, February 9th. Finally, TD Cowen upped their price target on Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a report on Monday, February 9th. Twelve analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company. According to data from MarketBeat.com, Biogen presently has an average rating of “Hold” and a consensus target price of $205.04.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.18% of the stock is currently owned by corporate insiders.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen presented additional Phase 1b data for salanersen in spinal muscular atrophy (SMA) showing new motor milestones, a supportive safety profile over one year, and the launch of a global Phase 3 program — news that increases the drug’s commercial and clinical probability upside. GlobeNewsWire: Salanersen Phase 1b
• Positive Sentiment: Additional media coverage emphasizes salanersen’s once-yearly dosing potential and the potential to address patients with suboptimal response to prior gene therapy — a clear positive for BIIB’s late-stage pipeline narrative. The Pharma Letter: Salanersen data
• Positive Sentiment: Analyst and market commentary is supportive: a Barchart piece notes BIIB is outperforming the healthcare sector, and Zacks highlights BIIB as a strong value stock — both reinforce investor sentiment and may attract relative-value and sector-rotation flows. Barchart: BIIB outperforming Zacks: Value case
• Positive Sentiment: Macro/market commentary from industry voices (Josh Brown) argues large-cap biotech is “growth without disruption risk,” which can boost investor appetite for established biotech names like BIIB. Josh Brown / 247wallst
• Neutral Sentiment: Biogen’s presentation transcript from the Leerink Global Healthcare Conference is available; such presentations can clarify near-term strategy but typically have incremental impact unless new guidance/data are revealed. Seeking Alpha: Leerink transcript
• Neutral Sentiment: Coverage summarizing Q4 winners/losers versus peers provides context on relative performance but did not report a new catalyst specific to Biogen. Yahoo Finance: Q4 winners & losers
• Neutral Sentiment: Short-interest entries in the feed show contradictory/erroneous values (zeros and NaN); there’s no reliable evidence here of a material increase in short-selling pressure.
• Neutral Sentiment: An article about a biogenic carbon removal project (Svante) appears unrelated to Biogen the biotech and is unlikely to affect BIIB’s stock. Financial Post: Svante CDR project

Biogen Stock Up 1.1%

Biogen stock opened at $190.48 on Thursday. The company has a market capitalization of $27.95 billion, a P/E ratio of 21.62, a PEG ratio of 1.50 and a beta of 0.15. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The stock has a 50-day simple moving average of $183.84 and a 200-day simple moving average of $166.32.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.61 by $0.38. The company had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm’s revenue was down 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities research analysts expect that Biogen Inc. will post 15.83 earnings per share for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.